Advanced Pulmonary Delivery of Peptides or Proteins Using Polymeric Particles

Delivery Technologies for Biopharmaceuticals: Peptides, Proteins, Nucleic Acids and Vaccines

Volumn , Issue , 2009, Pages 227-244

  Youn, Yu Seok ^a   Lee, Kang Choon ^b   Bae, You Han ^c   Na, Kun ^d   Lee, Eun Seong ^d  

^a Pusan National University   (South Korea)

^b Sungkyunkwan University   (South Korea)

^c UNIVERSITY OF UTAH   (United States)

^d The Catholic University of Korea   (South Korea)

Author keywords

Advanced pulmonary delivery of peptides or proteins using polymeric particles; Mass median aerodynamic diameter (MMAD); Particle size and pulmonary deposition location; Peptide and protein agent development new challenges to delivery methods; Polymeric microparticles for peptide and protein delivery; Polymeric particle formulations effective pulmonary delivery of peptides and proteins; Pulmonary bioavailabilities of peptides and proteins; Pulmonary delivery of peptides and proteins; Pulmonary macrophages and secretion of peroxidases immunomodulatory mediators; Supercritical fluid (SCF) drying processes protein friendly technique

Indexed keywords

EID: 84889283218     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470688397.ch12     Document Type: Chapter

References (71)

1. Agu, R.U., Ugwoke, M.I., Armand, M. et al. (2001) The lung as a route for systemic delivery of therapeutic proteins and peptides. Respir. Res., 2, 198-209.
2. Taluja, A., Youn, Y.S. and Bae, Y.H. (2007) Novel approach in microparticulate PLGA delivery systems encapsulating proteins. J. Mater. Chem., 17, 4002-4014.
3. Carino, G.P. and Mathiowitz, E. (1999) Oral insulin delivery. Adv. Drug Deliv. Rev., 35, 249-257.
4. Lee, V.H.L. and Yamamoto, A. (1990) Penetration and enzymatic barriers to peptide and protein absorption. Adv. Drug Deliv. Rev., 4, 171-207.
5. Patton, J.S., Fishburn, C.S. and Weers, J.G. (2004) The lungs as a portal of entry for systemic drug delivery. Proc. Am. Thorac. Soc., 1, 338-344.
6. Patton, J.S. and Byron, P.R. (2007) Inhaling medicines: delivering drugs to the body through the lungs. Nat. Rev. Drug Discov., 6, 67-74.
7. Patton, J.S. (1996) Mechanisms of macromolecular absorption by the lungs. Adv. Drug Deliv. Rev., 19, 3-36.
8. Adjei, A.L. and Gupta, P.K. (1997) Inhalation Delivery of Therapeutic Peptides and Proteins, Marcel Dekker, Inc, New York, p. 107.
9. Komada, F.S., Iwakawa, N., Yamamoto, H. et al. (1994) Intratracheal delivery of peptide and protein agents: absorption from solution and dry powder by rat lung. J. Pharm. Sci., 83, 863-867.
10. Okumura, K., Iwakawa, S., Yoshida, T. and Komada, F. (1992) Intratracheal delivery of insulin and absorption from solution and aerosol by rat lung. Int. J. Pharm., 88, 63-73.
11. Yamamoto, A., Umemori, S. and Muranishi, S. (1994) Absorption enhancement of intrapulmonary administered insulin by various absorption enhancers and protease inhibitors in rats. J. Pharm. Pharmacol., 46, 14-18.
12. Niven, R.W., Whitcomb, L., Kinstler, O. et al. (1994) The pulmonary absorption of aerosolized and intratracheally instilled rhG-CSF and monoPEGylated rhG-CSF. Pharm. Res., 12, 1343-1349.
13. Tronde, A., Norden, B., Marchner, H. et al. (2003) Pulmonary absorption rate and bioavailability of drugs in vivo in rats: structure-absorption relationships and physicochemical profiling of inhaled drugs. J. Pharm. Sci., 92, 1216-1233.
14. Kobayashi, S., Kondo, S. and Juni, K. (1994) Study on pulmonary delivery of salmon calcitonin in rats: effects of protease inhibitors and absorption enhancer. Pharm. Res., 11, 1239-1243.
15. Morita, T., Yamamoto, A., Takakura, Y. et al. (1994) Improvement of the pulmonary absorption of (Asu 1,7)-eel calcitonin by various protease inhibitors in rats. Pharm. Res., 11, 909-913.
16. Hussain, A., Arnold, J.J., Khan, M.A. and Ahsan, F. (2004) Absorption enhancers in pulmonary protein delivery. J. Control. Release, 94, 15-24.
17. Douglas, G.P., Wisniowski, J., Daugherty, G.L. et al. (1997) Nonimmune phagocytosis of liposomes by rat alveolar macrophages is enhanced by vitronectin and is vitronectin-receptor mediated. Am. J. Respir. Cell. Mol. Biol., 17, 462-470.
18. Patton, J.S., Nagarajan, S. and Clark, A. (1998) Pulmonary absorption and metabolism of peptides and proteins. Respir. Drug Deliv., 7, 17-24.
19. Youn, Y.S., Kwon, M.J., Na, D.H. et al. (2008) Improved intrapulmonary delivery of site-specific PEGylated salmon calcitonin: optimization by PEG size selection. J. Control. Release, 125, 68-75.
20. Niven, R.W. (1995) Delivery of biotherapeutics by inhalation aerosol. Crit. Rev. Ther. Drug Carrier Syst., 12, 151-231.
21. Boucher, R.C., Stutts, M.J. and Gatzy, J.T. (1981) Regional differences in bioelectric properties and ion flow in excised canine airways. J. Appl. Physiol., 51, 706-714.
22. Bitonti, A.J., Dumont, J.A., Low, S.C. et al. (2004) Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway. Proc. Natl. Acad. Sci. USA, 101, 9763-9768.
23. Low, S.C., Nunes, S.L., Bitonti, A.J. and Dumont, J.A. (2005) Oral and pulmonary delivery of FSH-Fc fusion proteins via neonatal Fc receptor-mediated transcytosis. Hum. Reprod., 20, 1805-1813.
24. Chono, S., Tanino, T., Seki, T. and Morimoto, K. (2006) Influence of particle size on drug delivery to rat alveolar macrophages following pulmonary administration of ciprofloxacin incorporated into liposomes. J. Drug Target., 14, 557-566.
25. Edwards, D.A., Hanes, J., Caponetti, G. et al. (1997) Large porous particles for pulmonary drug delivery. Science, 276, 1868-1871.
26. Chow, A.H.L., Tong, H.H.Y., Chattopadhyay, P. and Shekunov, B.Y. (2007) Particle engineering for pulmonary drug delivery. Pharm. Res., 24, 411-437.
27. Hinds, W.C. (ed.) (1999) Aerosol Technology: Properties, Behavior, and Measurement of Airbone Particles, 2nd edn, John Wiley & Sons, Inc.
28. Lee, E.S., Kwon, M.J., Lee, H. et al. (2006) In vitro study of lysozyme in poly(lactide-co-glycolide) microspheres with sucrose acetate isobutyrate. Eur. J. Pharm. Sci., 29, 435-441.
29. Kwon, M.J., Bae, J.H., Kim, J.J. et al. (2007) Long acting porous microparticles for pulmonary drug delivery. Int. J. Pharm., 333, 5-9.
30. Lee, E.S., Kwon, M.J., Na, K. and Bae, J.H. (2007) Protein release behavior from porous microparticle with lysozyme/hyaluronate ionic complex. Colloids Surfs. B., 55, 125-130.
31. Huang, Y.Y. and Wang, C.H. (2006) Pulmonary delivery of insulin by liposomal carriers. J. Control. Release, 113, 9-14.
32. Oyabu, T., Ogami, A., Morimoto, Y. et al. (2007) Biopersistence of inhaled nickel oxide nanoparticles in rat lung. Inhal. Toxicol., 19 (SUPPL. 1), 55-58.
33. Seville, P.C., Li, H.Y. and Learoyd, T.P. (2007) Spray-dried powders for pulmonary drug delivery. Crit. Rev. Ther. Drug Carrier Syst., 24, 307-360.
34. Bell, J. and Newman, S. (2007) The rejuvenated pressurized metered dose inhaler. Expert Opin. Drug Deliv., 4, 215-234.
35. Kleinstreuer, C., Zhang, Z. and Donohue, J.F. (2008) Targeted drug-aerosol delivery in the human respiratory system. Annu. Rev. Biomed. Eng., 10, 195-220.
36. Shoyele, S.A. (2008) Engineering protein particles for pulmonary drug delivery. Methods Mol. Biol., 437, 149-160.
37. Koushik, K., Dhanda, D.S., Cheruvu, N.P.S. and Kompella, U.B. (2004) Pulmonary delivery of deslorelin: Large porous PLGA particles and HP β CD complexes. Pharm. Res., 21, 1119-1126.
38. Jones, J. (1984) Clearance of inhaled particles from the alveoli, in Aerosol and the Lung: Clinical and Experimental Aspects (ed. S.W. Clarke), Butterworth, London, pp. 49-70.
39. Donaldson, K., Borm, P.J., Oberdorster, G. et al. (2008) Concordance between in vitro and in vivo dosimetry in the proinflammatory effects of low-toxicity, low-solubility particles: the key role of the proximal alveolar region. Inhal. Toxicol., 20, 53-62.
40. Rogueda, P.G. and Traini, D. (2007) The nanoscale in pulmonary deliver. Part 1: deposition, fate, toxicology and effects. Expert Opin. Drug Deliv., 4, 595-606.
41. Inoue, K., Takano, H., Yanagisawa, R. et al. (2007) Effect of nanoparticles on lung physiology in the presence or absence of antigen. Int. J. Immunopathol. Pharmacol., 20, 737-744.
42. Karathanasis, E., Bhavane, R. and Annapragada, A.V. (2007) Glucose-sensing pulmonary delivery of human insulin to the systemic circulation of rats. Int. J. Nanomedicine, 2, 501-513.
43. Yamamoto, H., Kuno, Y., Sugimoto, S. et al. (2005) PLGA nanosphere with chitosan improved pulmonary delivery of calcitonin by mucoadhesion and opening of the intercellular tight junctions. J. Control. Release, 102, 373-381.
44. Amidi, M., Pellikaan, H.C., de Boer, A.H. et al. (2008) Preparation and physicochemical characterization of supercritically dried insulin-loaded microparticles for pulmonary delivery. Eur. J. Pharm. Biopharm., 68, 191-200.
45. Chung, H.J., Kim, I.K., Kim, T.G. and Park, T.G. (2008) Highly open porous biodegradable microcarriers: in vitro cultivation of chondrocytes for injectable delivery. Tissue Eng. Part A, 14 (5), 607-615.
46. Kim, H.K., Chung, H.J. and Park, T.G. (2006) Biodegradable polymeric microspheres with ' open/closed ' pores for sustained release of human growth hormone. J. Control. Release, 112, 164-174.
47. Chung, H.J., Kim, H.K., Yoon, J.J. and Park, T.G. (2006) Heparin immobilized porous PLGA microspheres for angiogenic growth factor delivery. Pharm. Res., 23, 1835-1841.
48. Arnold, M.M., Gorman, E.M., Schieber, L.J. et al. (2007) Cipro encapsulation in monodisperse large porous PLGA microparticles. J. Control. Release, 121, 100-109.
49. Bot, A.I., Tarara, T.E., Smith, D.J. et al. (2000) Novel lipid-based hollow-porous microparticles as a platform for immunoglobulin delivery to the respiratory tract. Pharm. Res., 17, 275-283.
50. Kreuter, J. (1991) Nanoparticle-based drug delivery systems. J. Control. Release, 16, 169-176.
51. Sung, J.C., Pulliam, B.L. and Edwards, D.A. (2007) Nanoparticles for drug delivery to the lungs. Trends Biotechnol., 25, 563-570.
52. Kawashima, Y., Yamamoto, H., Takeuchi, H. et al. (1999) Pulmonary delivery of insulin with nebulized-lactide/glycolide copolymer (PLGA) nanospheres to prolong hypoglycemic effect. J. Control. Release, 62, 279-287.
53. Zhang, Q., Shen, Z. and Nagai, T. (2001) Prolonged hypoglycemic effect of insulin-loaded polybutylcyanoacrylate nanoparticles after pulmonary administration to normal rats. Int. J. Pharm., 218, 75-80.
54. Tseng, C.-L., Wang, T.-W., Dong, G.-C. et al. (2007) Development of gelatin nanoparticles with biotinylated EGF conjugation for lung cancer targeting. Biomaterials, 28, 3996-4005.
55. Grenha, A., Seijo, B. and Remunan-Lopez, C. (2005) Microencapsulated chitosan nanoparticles for lung protein delivery. Eur. J. Pharm. Sci., 25, 427-437.
56. Tsapis, N., Bennett, D., Jackson, B. et al. (2002) Trojan particles: large porous carriers of nanoparticles for drug delivery. Proc. Natl. Acad. Sci. USA, 99, 12001-12005.
57. Sham, J.O.H., Zhang, Y., Finlay, W.H. et al. (2004) Formulation and characterization of spray-dried powders containing nanoparticles for aerosol delivery to the lung. Int. J. Pharm., 269, 457-467.
58. Hadinoto, K., Zhu, K. and Tan, R.B.H. (2007) Drug release study of large hollow nanoparticulate aggregates carrier particles for pulmonary delivery. Int. J. Pharm., 341, 195-206.
59. Fiegel, J., Fu, J. and Hanes, J. (2004) Poly(ether-anhydride) dry powder aerosols for sustained drug delivery in the lungs. J. Control. Release, 96, 411-423.
60. Fu, J., Fiegel, J., Krauland, E. and Hanes, J. (2002) New polymeric carriers for controlled drug delivery following inhalation or injection. Biomaterials, 23, 4425-4433.
61. Huang, Y.C., Yeh, M.K. and Chiang, C.H. (2002) Formulation factors in preparing BTM-chitosan microspheres by spray drying method. Int. J. Pharm., 242, 239-242.
62. Surendrakumar, K., Martyn, G.P., Hodgers, E.C.M. et al. (2003) Sustained release of insulin from sodium hyaluronate based dry powder formulations after pulmonary delivery to beagle dogs. J. Control. Release, 91, 385-394.
63. Hamdi, G., Ponchel, G., Besnard, M. and Duchene, D. (1999) Loading and in vitro release of salbutamol from degradable cross-linked starch microspheres intended for pulmonary administration. STP Pharma Sci., 9, 573-577.
64. Davidson, I.G., Langner, E.J., Plowman, S.V. and Blair, J.A. (2003) Release mechanism of insulin encapsulated in trehalose ester derivative microparticles delivered via inhalation. Int. J. Pharm., 254, 211-222.
65. Shinha, V.R. and Trehan, A. (2003) Biodegradable microspheres for protein delivery. J. Control. Release, 90, 261-280.
66. De Rosa, G., Iommelli, R., La Rotonda, M.I. et al. (2000) Influence of the co-encapsulation of different non-ionic surfactants on the properties of PLGA insulin-loaded microspheres. J. Control. Release, 69, 283-295.
67. Baker, G.L., Gupta, A., Clark, M.L. et al. (2008) Inhalation toxicity and lung toxicokinetics of C60 fullerene nanoparticles and microparticles. Toxicol. Sci., 101, 122-131.
68. Deguchi, S., Yamazaki, T., Mukai, S.A. et al. (2007) Stabilization of C60 nanoparticles by protein adsorption and its implications for toxicity studies. Chem. Res. Toxicol., 20, 854-858.
69. Huang, Y.C., Vieira, A., Huang, K.L. et al. (2005) Pulmonary inflammation caused by chitosan microparticles. J. Biomed. Mater. Res. A, 75, 283-287.
70. Brzoska, M., Langer, K., Coester, C. et al. (2004) Incorporation of biodegradable nanoparticles into human airway epithelium cells-in vitro study of the suitability as a vehicle for drug or gene delivery in pulmonary diseases. Biochem. Biophys. Res. Commun., 318, 562-570.
71. Wegesser, T.C. and Last, J.A. (2008) Lung response to coarse PM: bioassay in mice. Toxicol. Appl. Pharmacol., 230 (2), 159-166.